GlassScriptPhysician profile
Elisse Gray
NPI 1386147056
$18,047.55
in general payments reported to CMS, 2019-2025
39 companies · $4,045 in 2025
The $4,045 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,342 · 2022: $3,936 · 2023: $2,827 · 2024: $4,898 · 2025: $4,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $78.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,691.35 |
| Education | $78.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,328.58 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Harmony Biosciences LLC | $1,727.46 | 2021-2025 | Wakix |
| Glaxosmithkline, LLC. | $1,713.45 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,206.34 | 2021-2025 | |
| Insmed, INC. | $1,183.11 | 2021-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $975.68 | 2021-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $973.86 | 2021-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $954.19 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.54 | 2021-2023 | Stiolto Respimat, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $509.86 | 2021-2025 | Glassia |
| Genentech USA, INC. | $484.75 | 2021-2025 | Xolair |
| Mylan Specialty L.P. | $477.22 | 2021-2024 | Yupelri |
| Inspire Medical Systems, INC. | $451.00 | 2023-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $401.46 | 2021-2025 | Opsumit, Uptravi |
| Baxter Healthcare | $376.56 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $366.07 | 2021-2025 | Tezspire |
| Axsome Therapeutics, INC. | $357.07 | 2023-2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $354.53 | 2021-2024 | |
| Electromed, INC. | $324.86 | 2021-2025 | Smartvest |
| Philips North America LLC | $317.43 | 2021-2023 | |
| United Therapeutics Corporation | $280.25 | 2021-2025 | Tyvaso, Tyvaso |
| Vifor Pharma, INC. | $245.18 | 2024-2025 | Zemaira |
| Noctrix Health, INC. | $222.55 | 2025 | Nidra |
| Avadel Cns Pharmaceuticals, LLC | $209.80 | 2023-2025 | Lumryz |
| Verona Pharma, INC. | $135.43 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $127.04 | 2021 | |
| Viatris Specialty LLC | $98.62 | 2025 | Yupelri |
| Pfizer INC. | $91.22 | 2021-2025 | |
| Inogen, INC. | $71.39 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Paratek Pharmaceuticals, INC. | $67.08 | 2022 | |
| Medtronic, INC. | $62.64 | 2022 | |
| Lilly USA, LLC | $54.92 | 2025 | Zepbound, Mounjaro |
| Mallinckrodt Hospital Products INC. | $33.55 | 2022 | |
| Resmed Corp | $30.56 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $28.24 | 2021 | |
| Advanced Respiratory, INC | $23.89 | 2021 | |
| Zoll Respicardia, INC. | $23.27 | 2023 | Remede System |
| Gilead Sciences, INC. | $20.88 | 2021 | |
| Tactile Systems Technology INC | $17.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisse Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.